Nucleostemin (NS), a nucleolar GTPase, is highly expressed in stem/progenitor cells and in most cancer cells. However, little is known about the regulation of its expression. Here, we identify the NS gene as a novel direct transcriptional target of the c-Myc oncoprotein. We show that Myc overexpression enhances NS transcription in cultured cells and in pre-neoplastic B cells from El-myc transgenic mice. Consistent with NS being downstream of Myc, NS expression parallels that of Myc in a large panel of human cancer cell lines. Using chromatin immunoprecipitation we show that c-Myc binds to a well-conserved E-box in the NS promoter. Critically, we show NS haploinsufficiency profoundly delays Myc-induced cancer formation in vivo. NS þ /ÀEl-myc transgenic mice have much slower rates of B-cell lymphoma development, with life spans twice that of their wild-type littermates. Moreover, we demonstrate that NS is essential for the proliferation of Myc-overexpressing cells in cultured cells and in vivo: impaired lymphoma development was associated with a drastic decrease of c-Myc-induced proliferation of pre-tumoural B cells. Finally, we provide evidence that in cell culture NS controls cell proliferation independently of p53 and that NS haploinsufficiency significantly delays lymphomagenesis in p53-deficient mice. Together these data indicate that NS functions downstream of Myc as a rate-limiting regulator of cell proliferation and transformation, independently from its putative role within the p53 pathway. Targeting NS is therefore expected to compromise early tumour development irrespectively of the p53 status.
Introduction
Deregulation of Myc oncoproteins is estimated to contribute to 70% of all human cancers Dang et al., 2006; Vita and Henriksson, 2006) . c-Myc overexpression is sufficient to drive quiescent cells into cycle and to accelerate their rate of cell cycle traverse (Bouchard et al., 1998) . Cells respond to this hyperproliferative signal by activating apoptosis (Askew et al., 1991; Evan et al., 1992) , at least in part by activating the ARF-p53 tumour suppressor pathway (Zindy et al., 1998; Eischen et al., 1999) or by repressing the expression of anti-apoptotic proteins Bcl-2 and Bcl-XL (Eischen et al., 2001) . Bypass of these cell cycle checkpoints and apoptotic pathways is a hallmark of Myc-driven cancers.
c-Myc is a transcription factor that can either activate or repress gene expression. Activation occurs through dimerization with the partner protein Max, and binding to the consensus DNA sequence CACGTG (E-box). Repression occurs through association of c-Myc/Max dimers with other transcription factors, such as Miz-1 or NF-Y, and interference with their function (Izumi et al., 2001; Staller et al., 2001; Seoane et al., 2002; Mao et al., 2003) , although it is becoming apparent that c-Myc may also repress transcription through E-boxes (Adhikary and Eilers, 2005) . On the basis of chromatin immunoprecipitation (ChIP) a number of studies have suggested that c-Myc has the potential to activate thousands of genes, which in turn coordinate a wide range of cellular processes including those essentials for cell cycle, growth and apoptosis but also ribosome biogenesis, metabolism, protein folding and self-renewal (Fernandez et al., 2003; Li et al., 2003; Zeller et al., 2006; Chen and Olopade, 2008; Eilers and Eisenman, 2008; Kidder et al., 2008; Kim et al., 2008; Perna et al., 2011) . Associating specific targets of c-Myc to its diverse biological effects is therefore a challenge. Although Myc's ability to promote cellular transformation is well established, a better understanding of the mechanisms through which Myc mediates tumourigenesis is essential for the development of therapeutic approaches to target this potent oncoprotein.
Using expression profiling to search for novel Myc targets we have identified nucleostemin (NS), a nucleolar GTP-binding protein that is overexpressed in many cancer cell lines and in mouse and human primary tumours (Tsai and McKay, 2002; Liu et al., 2004; Sijin et al., 2004; Han et al., 2005; Ye et al., 2008; Malakootian et al., 2010; Zhang and Wang, 2010) . Accumulating evidence indicates that high NS levels may contribute to the high proliferative capacity of tumour cells and therefore to tumourigenesis: NS overexpression in mouse mammary tumour cells enhances tumourigenesis (Lin et al., 2010) . Knocking down (KD) NS expression reduces cell proliferation of cultured osteosarcoma cells (Tsai and McKay, 2002) ; it also decreases the tumourigenicity of HeLa cells on injection into nude mice (Sijin et al., 2004) . However, it is not known whether decreasing NS function would be sufficient to inhibit the tumour development in a spontaneous cancer genetic model.
Several studies have provided important insights into the molecular mechanisms of action of NS. NS growthpromoting activity has been proposed to result from its direct interaction with p53 (Tsai and McKay, 2002; Bernardi and Pandolfi, 2003) . But genetic experiments in vivo have highlighted p53-independent role of NS in the control cell proliferation: the early embryonic lethality of NS-deficient embryos, which results from an overall cell proliferation defect is not rescued on a p53-null background (Beekman et al., 2006) . In keeping, NS is required for the proliferation of normal rat bone marrow stem cells in a p53-independent manner (Jafarnejad et al., 2008) . NS may also contribute to cell proliferation via its role as an integrated component of ribosome biogenesis, particularly pre-rRNA processing (Romanova et al., 2009) . NS forms a large protein complex that co-fractionates with the pre-60 S ribosomal subunit and contains proteins related to pre-rRNA processing and several ribosomal proteins (RPs). NS KD retards rRNA processing, thereby causing the accumulation of free RPs and induction of ribosome stress (Romanova et al., 2009) . Interestingly, NS role in ribosome biogenesis might be connected to its contribution to the regulation of the p53 pathway. RPs can indeed directly bind MDM2 and interfere with MDM2-dependent degradation of p53 Jin et al., 2004) . Depletion of NS induced the interaction between some RPs (RPL5 and RPL11) and MDM2, and KD the RPs reversed, at least partly, p53-dependent arrest caused by NS depletion (Dai et al., 2008) . These data therefore provide an alternative explanation for the p53-dependent role of NS in the control of cancer cell proliferation (Lo and Lu, 2010) . Hence, targeting NS in tumours in which the p53 pathway is intact may offer a way for eradicating growing cancer cells by cutting off the ribosome supplies for protein production, which is necessary for actively growing cancer cells and/or for activating a p53 tumour suppression response.
Little is known about what drives the high NS expression in cancer cells. Here, we show that NS is a direct transcriptional target of c-Myc and that it is a critical downstream regulator of Myc's ability to induce accelerated cell proliferation and cancer formation. In addition, we address the relevance of NS-dependent inhibition of p53 function in relation to cancer cell proliferation. We show that NS is haploinsufficient in the control of proliferation of cancer-initiating cells and tumourigenesis in vivo, in a p53-independent manner. Our data indicate that targeting NS may be therapeutically efficacious in tumors driven by c-Myc, irrespective of the p53 status.
Results

Search for novel c-Myc-induced transcriptional targets
Overexpression of the c-Myc oncoprotein is a feature of a many human cancers. To identify novel transcriptional targets that have a critical role in c-Myc-induced tumourigenesis, we searched for genes that are differentially expressed upon c-Myc overexpression using a microarray-based approach. As a cellular model, we used human lung fibroblast-derived cells (LF1; Brown et al., 1997) immortalized with the catalytic subunit of telomerase and the simian virus 40 large T and small T antigens (LF1/TERT/LT/ST; Wei et al., 2003) , referred to herein as LF1 c. c-Myc overexpression in this cell line causes a significant increase in cell proliferation and induction of anchorage-independent growth in soft agar (Brown et al., 1997; Wei et al., 2003) . Global gene expression was determined in both parental (LF1 c) and stably c-Myc-expressing (LF1 Myc) cell lines using the Affymetrix Human Genome U133 array platform (Affymetrix, Santa Clara, CA, USA). Of the 44 928 probe sets analyzed, 464 showed statistically significant differences in gene expression using a cutoff of more thantwofold between the parental and c-Myc-expressing cells (Po0.05). Comparison of our list of putative cMyc-upregulated genes (193 out of the 464 probe sets) with the previously reported list of c-Myc-bound genomic loci, as determined by a ChIP on chip in HL60 cells (Mao et al., 2003) , identified four common genes, which are likely to be direct c-Myc-transcriptional targets: H2BFG, OIP2, DLEU1 and E2IG3, also known as NS. In addition, going back to one of our previously published microarray experiments, we noticed that the gene previously referred to as 'hypothetical GTP-binding protein' (accession no. AA892598) was in fact NS. According to these data NS expression is significantly elevated in rat fibroblast cell line with endogenous c-Myc (TGR) and in c-Myc-null fibroblasts reconstituted with exogenous c-Myc expression (Myc3) compared with c-Myc-null fibroblasts (HO; O'Connell et al., 2003) . Hence, the ability of c-Myc to induce NS appears to be evolutionarily conserved.
NS is a direct Myc target
We confirmed NS upregulation in Myc-overexpression LF1 c cells and in c-Myc-expressing rat fibroblasts (TGR and Myc3) using reverse transcriptase-quantitative PCR (RT-qPCR) and western blot analysis (Figures 1a and b) . We also analyzed the expression of NS in rat fibroblasts (TGR) under conditions of serum starvation, which decreases Myc mRNA and protein expression, and at various time points following serum stimulation. c-Myc is rapidly induced on serum addition, peaking at around 4 h post-stimulation (Dang et al., 2006) . RT-qPCR confirmed Myc induction upon serum stimulation and a concomitant increase in NS expression was observed, consistent with NS being regulated by c-Myc (Figure 1c) . Similarly, NS downregulation paralleled that of c-Myc at later time points.
Cross-species comparison of the rat, mouse and human NS promoter identified a canonical c-Mycbinding site (E-box sequence: 5 0 -CACGTG-3 0 ) B60 bp upstream of the transcription start site. To determine whether c-Myc can directly bind to this E-box we performed ChIP assays in both TGR rat and LF1 c human fibroblasts. TGR fibroblasts were starved and serum stimulated for 4 h. The protein-DNA complexes were immunoprecipitated with a polyclonal c-Myc antibody ('Myc'; Figure 1d ) or without antibody ('NoAb') as a negative control. The immunoprecipitated DNA was analyzed using qPCR. We observed a 4.5-fold enrichment for c-Myc binding at the NS E-box on serum stimulation (Figure 1d ). A fragment containing the E-box of the known c-Myc target Nucleolin was used as a positive control. Fragments devoid of any E-box (CHRNB4; Frank et al., 2001) or containing the E-box of glycine methyltransferase (GNMT), a gene which is not regulated by c-Myc, were used as negative controls. Sevenfold enrichment in c-Myc binding to the NS E-box was also observed in c-Myc-overexpressing LF1 Myc fibroblasts as compared with the parental LF1c cells (Figure 1e ). Fragments containing the E-box of the CAD gene and PAPT, a gene that is not regulated by Myc, were used here as positive and negative controls, respectively (Fernandez et al., 2003; Brodsky et al., 2005) . Together these data indicate that c-Myc is directly recruited to the E-box present in the NS promoter, implying that NS is a direct transcriptional target of c-Myc.
To confirm that c-Myc can induce NS expression in vivo we analyzed NS expression in the Em-myc transgenic mice. These mice express high levels of c-Myc in the B-cell lineage and develop pre-B and/or B-cell lymphoma with mean survival of about 11 weeks (Adams et al., 1986) . Although NS protein level is low in wild-type bone marrow and spleen, which mainly contain early progenitors and mature B-cells, respectively, it is significantly elevated in spleen and in tumors of the Em-myc tumor-bearing mice ( Figure 1f ). As expected, NS protein levels in the spleens of NS þ /À mice are approximately half of that in wild-type (NS þ / þ ) mice ( Figure 1f ). NS mRNA, as measured by RT-qPCR, is significantly elevated in the spleen of the Em-myc tumor-free mice and perfectly parallels the level of Myc in spleen and lymphoma from the Em-myc tumor-bearing mice ( Figure 1g ). These data further confirm that that NS transcription is directly induced by Myc in vivo.
We next tested whether there is a correlation between c-Myc and NS expression in human cancers. To this end, we searched for genes whose expression profiles are most similar to c-Myc in a large panel of human cell lines (NCI60) using the NCI's Cancer Genome Anatomy Project database. Of the 6817 genes in the database, NS was among top 10 genes whose expression profile was most similar to c-Myc (Figure 1h ). Thus, cMyc and NS are co-expressed in human cancers, which is consistent with NS being downstream of c-Myc.
NS haploinsufficiency protects mice from Myc-induced tumourigenesis
We next asked whether high levels of NS are required downstream of c-Myc to facilitate c-Myc-induced tumorigenesis. Unlike NS-null mice, NS þ /À mice appear normal, despite a 50% reduction in NS protein levels. To test whether loss of one NS allele affects Myc-induced lymphoma development NS þ /À mice were bred onto a C57/Bl6 background for more than six generations and were then crossed to C57/Bl6 Em-Myc transgenics. Lymphoma development was then followed in NS þ / þ ; Em-Myc and NS þ /À; Em-Myc animals. As expected, most NS þ / þ ; Em-Myc succumbed to lethal lymphoma between 90 and 200 days ( Figure 2 ). Strikingly, lymphoma development was profoundly delayed in NS þ /À; Em-Myc mice as compared with NS þ / þ ; Em-Myc littermates (Figure 2 ; Po0.0001, log-rank test). The mean survival of NS þ /À; Em-Myc mice was twice that of the mean survival of the NS þ / þ ; Em-Myc littermates ( Figure 2 ). All NS þ / þ mice died within 40 weeks (n ¼ 24), whereas 50% (13 out of 26) of the NS þ /À animals were still alive at that time. The lymphomas that developed in NS þ /À; Em-Myc animals were typical pre-B/B-cell lymphomas that arise in Em-Myc mice. We conclude that NS haploinsufficiency markedly compromises c-Myc-mediated tumourigenesis.
NS is a critical regulator of Myc-induced cell proliferation
Having established the relevance of NS in c-Mycinduced tumourigenesis, we next investigated the underlying mechanism by dissecting the role of NS in c-Myc functions. We knocked down NS by siRNA in an established embryonic rat fibroblast Rat1A cell line expressing an inducible form of c-Myc, the c-Myc/ estrogen receptor (ER) fusion protein (Mai et al., 1996) . NS expression increased as a result of c-Myc induction (c siRNA þ 4-hydroxytamoxifen) and transfection of NS siRNAs completely prevented this upregulation (Figure 3a ). In agreement with its oncogenic nature, increased levels of c-Myc drive cellular proliferation. NS KD had only a marginal effect on cell proliferation in the absence of c-Myc induction in this experimental setting; however, preventing c-Myc-induced NS upregulation by siRNA profoundly decreased cell proliferation upon 4-hydroxytamoxifen-mediated c-Myc induction ( Figure 3b ). As expected, in addition to stimulating cell proliferation c-Myc-induction promoted spontaneous apoptosis (Meyer et al., 2006) . However, we did not observe any effect of NS KD on the extent of Myc-induced apoptosis in this experimental setting (data not shown).
Induction of c-Myc in Rat1A Myc/ER cells causes anchorage-independent growth in soft agar (Qi et al., ChIP was performed with a polyclonal c-Myc antibody (Upstate), or with no antibody (negative control), in TGR cells that were serum starved to prevent c-Myc expression (0 h), or serum stimulated for four hours to induce c-Myc expression (4 h). qPCR was performed using primers spanning a NS E-box, a Nucleolin E-box (positive control), a promoter with an E-box that has been previously shown not be bound by c-Myc (GNMT, negative control) and a promoter with no E-box (CHRNB4, negative control). (e) c-Myc binds directly to the NS promoter in human cells. ChIP was performed in LF1 control cells (LF1 c) and in LF1 cells with c-Myc overexpression (LF1 Myc), using c-Myc antibody (Upstate), or no antibody (negative control). qPCR primers were spanning: NS E-box, CAD E-box (positive control) and a gene not expressed in LF1 cells, testis specific poly(A) polymerase b (PAPT; negative control). (f) NS is highly overexpressed in all c-Myc-driven lymphoma-related tissues but not in healthy spleens. Western blot analysis on spleens (S) and tumours (T) derived from NS þ / þ ; Em-Myc and NS þ /À; Em-Myc. Lysates from healthy spleens from NS þ /À and WT C57BL/6 mice were used as controls. Vinculin served as a loading control. Two splicing variants of NS are detected with anti-NS antibody (Malakootian et al., 2010) . S -healthy spleen, I S , lymphoma-infiltrated spleen; T, tumour. (g) NS mRNA expression strongly correlates with c-Myc expression. As expected, NS mRNA levels in spleens (S) from non-c-Myc-overexpressing N þ /À animals are about half of the ones detected in the wild-type (NS þ / þ ) mice. In spleens from Em-Myc animals (Em-Myc) the difference becomes less pronounced because of strong c-Myc-driven transactivation of NS expression. I S , lymphoma-infiltrated spleen; S, healthy spleen; T, tumour. Relative expression levels are presented as averages from three mice per each genotype. (h) Expression of NS correlates with c-Myc expression in the NC60 cancer cell lines. Analysis of a data set available from the National Cancer Institute's Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/) reporting expression profiles for 6817 genes across 60 cancer cell lines. Red, high expression; blue, low expression. NS was included as one of the 10 genes with expression profiles most similar to c-Myc. To confirm these findings in vivo we assessed cell proliferation in response to Myc overexpresion in the Em-Myc transgenic mice using BrdU incorporation assays and fluorescence-activated cell sorting (FACS) analyses. As expected, we observed an increase in the rate of cell cycle progression, as monitored by BrdU incorporation, both in bone marrow and splenic pretumoral B cells from the Em-Myc mice (Figure 3d) . Consistently, the percentage of Em-Myc-positive cells in S phase of the cell cycle was markedly increased compared with wild-type cells (Figures 3e and f) . Importantly, a decrease in cell proliferation was observed in normal pre-B cells of NS þ /À mice compared with NS þ / þ mice, and this difference was more pronounced in the pre-tumoral B cells that expressed Myc (Figures 3d-f) . We therefore conclude that NS is a ratelimiting factor in pre-B-cell proliferation and that NS haploinsufficiency limits the ability of Myc to efficiently drive their proliferation and expansion in vivo.
Myc overexpression induces p53-dependent apoptosis partly by inducing expression of the Mdm2-antagonist Arf (Dominguez-Sola et al., 2007) and partly by promoting a DNA-damage response (Vafa et al., 2002; Ray et al., 2006; Wang et al., 2008) . Accordingly, caspase3/7 glow assays and FACS analysis revealed a significant increase in apoptosis in pre-tumoral B cells of the Em-Myc mice as compared with their wild-type counterparts (Figure 3e and data not shown). As expected, we observed stabilization of p53 and induction Ser-18 phosphorylation of p53 in pre-tumoral and tumoral B cells of the Em-Myc mice, an event that occurs specifically in response to DNA-damage response (Chao et al., 2000) . However, the extent of p53 stabilization and phosphorylation and the percentage of spontaneous apoptotic cells were comparable in NS þ /À; Em-Myc and NS þ / þ ; Em-Myc animals ( Figure 3f ). Hence, consistent with our in vitro data, NS þ /À mice do not have a defect in DNA-damage response signaling or p53-dependent apoptotic response on a sensitized Em-Myc background.
NS is required for cell proliferation and tumourigenesis independently of p53
Previous transfection studies indicated that NS dampens p53-mediated growth suppression, through a direct physical interaction with p53 (Tsai and McKay, 2002) . We therefore tested whether the critical role for NS in the regulation of cell proliferation and tumourigenesis uncovered in our study is linked to its ability to regulate p53 function. We established stable NS KD lines in the human colon cancer cells lines HCT116 and isogenic HCT116 p53KO. c-Myc and NS were expressed at high levels in both parental HCT116 and HCT116 p53KO cell lines (data not shown). A robust NS KD was observed in both of these cell lines upon infection with two different lentiviral NS-shRNA constructs (Figure 4a ). Strikingly NS KD decreased the ability of these cells to grow in vitro irrespective of p53 status as assessed using growth curve assays, FACS analysis and soft agar assays (Figures 4b-d) . The FACS analysis indicated that NS KD resulted in a decreased percentage of cells in S-phase and an increased proportion of cells in the G2/M phase of the cell cycle. The cell cycle block was accompanied by an increase in the sub-G1 fraction, which likely result from increased cell death. Importantly, these growth inhibitory effects were observed in both p53 competent and p53KO cells.
To assess a putative p53-dependent role of NS in tumour formation, NS heterozygous mice were crossed with p53-null mice (Jacks et al., 1994) . T-cell development proceeds normally in p53-deficient mice although they eventually succumb to thymic lymphomas between 15 and 25 weeks of age (Donehower et al., 1992) and only few of them survive past week 30 (Hursting et al., 1994) . Strikingly, partial reduction of NS expression Suppression of Myc oncogenic activity AK Zwolinska et al was sufficient to significantly delay tumor formation in p53-null mice and extended their mean survival twofold (log-rank test: Po0.001; Figure 5 ). In all, 4 out of 19 NS þ /À; p53-null mice survived past 40 weeks wherease all 6 NS þ / þ controls died within 30 weeks. Thus, NS haploinsufficiency delays lymphomagenesis in a manner that is independent of its role in the regulation of p53 function. 
Suppression of Myc oncogenic activity AK Zwolinska et al
Discussion
The mechanisms leading to the widespread upregulation of NS in various human cancer cell lines and primary tumours are poorly understood. Previous reports have pointed at a correlation between NS expression and the presence of the active c-Myc (Rosenwald et al., 2002; Dave et al., 2006; Shaffer et al., 2006) . In this manuscript we extend this correlation to a large panel of human cancer cell lines (NC60) and show dramatic accumulation of NS in c-Myc-driven B-cell lymphomas isolated from Eu-Myc mice. Importantly, by identifying NS as a novel direct c-Myc-transcriptional target we provide for the first time direct mechanistic insights underlying the correlation between c-Myc and NS. As c-Myc is frequently activated in human malignancies our findings also provide an explanation for the upregulation of NS in human cancers, although we cannot exclude that additional mechanisms might contribute to the high NS expression. Critically, our data indicate that NS is not just another component of the complex transcriptional networks induced by c-Myc; instead we show that it is a critical regulator of tumor development and a key mediator of cMyc-induced tumourigenesis in vivo. Decreasing NS levels by 50% (haploinsufficiency) is sufficient to drastically limit c-Myc-induced lymphoma development in vivo. Our data indicate that this delay is not a consequence of an impaired DNA-damage response or p53-dependent apoptotic response but rather of an altered ability of cMyc to accelerate cell cycle progression in the tumorinitiating cells. Although the exact biochemical mechanism underlining the role of c-Myc-induced NS in cell proliferation awaits further studies it could be linked to its previously recognized role in ribosome biogenesis. Depletion of NS indeed retards rRNA processing, thereby causing free RPs accumulation, accompanied by a substantial decrease in overall protein synthesis (Romanova et al., 2009) . Interestingly, c-Myc is known to regulate ribosome biogenesis and translation by upregulating the transcription of rRNA and RPs and auxiliary factors that are required for rRNA processing, ribosome assembly and export of mature ribosomal subunits from the nucleus to the cytoplasm (van Riggelen et al., 2010) . The ability of c-Myc to regulate the expression of yet another regulator of this process, NS, is entirely consistent with this view. Importantly, an increasing number of observations indicate that c-Myc's contribution to tumourigenesis is at least partly connected to its ability to modulate ribosome biogenesis. In Eu-Myc mice, the same model system utilized in the study herein, loss of one allele of Rpl24 or Rpl38 decreased the incidence of lymphoma by 20% and delayed tumour onset by over 100 days (Barna et al., 2008) . Notably, similarly to what we have observed for NS, decreased Rlp24 gene dosage impeded the ability of c-Myc to stimulate cell cycle progression independently from the cell cycle program established at the transcriptional level by c-Myc hyperactivation. By analogy it is therefore tempting to speculate that c-Myc-induced cell proliferation and tumourigenesis might dependent on c-Myc's ability to stimulate ribosome biogenesis and protein synthesis, at least in part via induction of NS expression.
However, we also show that the function of NS in tumourigenesis is independent of its role in the regulation of the p53 tumor suppressor pathway. Indeed, reducing NS dose by half (NS þ /À) was sufficient to significantly delay lymphomagenesis on a p53-null background. This observation contrasts with the finding that Rpl24 or Rpl38 haploinsufficiencies do not have any effect on tumor formation in the context of the p53-null background (Barna et al., 2008) . Together these data raise the possibility that while RP and NS haploinsufficiencies similarly affect tumourigenesis they might still do so, at least partly, via distinct mechanisms.
Finally, our data indicate that in contrast to strategies targeting MDM2/MDMX, the efficacy of which relies on the presence of an intact p53 pathway (Toledo and Wahl, 2007; Marine, 2010) , targeting NS could represent an alternative valuable therapeutic approach in the management of cancers with a disabled p53 pathway. The presence of two putative GTP-binding sites within NS makes it a potential target for molecules that mimic or compete for GTP binding. It has recently been reported that AVN-944, a potent specific inosine monophosphate dehydrogenase inhibitor, currently in Phase I trials for the treatment of hematologic malignancies and in Phase II trials for solid tumors, leads to the rapid MDM2-dependent degradation of NS in tumor cell lines (Huang et al., 2009) . The effect is a consequence of targeting of the GTP-uncoupled NS for proteasomal degradation by MDM2 and appears to be specific as it was not observed with the two other nucleolar proteins nucleophosmin and nucleolin. Modulation of NS levels using AVN-944 could therefore be particularly effective in tumours overexpressing MDM2.
Materials and methods
Cell lines and culture conditions Human LF1 (Brown et al., 1997) expressing the catalytic subunit of telomerase (hTERT), simian virus 40 LT and simian virus 40 ST, and c-Myc (Wei et al., 2003) were cultured in Ham's F10 nutrient mixture supplemented with 15% fetal bovine serum. The pair of p53 þ / þ and p53 À/À human colon cancer cells HCT116 was obtained from Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA). The cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Immortalized embryonic Rat-1 fibroblast lines including TGR-1 (TGR; Prouty et al., 1993) , TGR-1-bearing homozygous c-myc deletion HO15.19 (HO; Mateyak et al., 1997) HO cells reconstituted with c-Myc expression (Myc3; Mateyak et al., 1999) and Rat1A expressing the Myc/ER fusion protein (obtained from S McMahon, Kimmel Cancer Center, Philadelphia, PA, USA) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% calf serum (Hyclone, Waltham, MA, USA). For the experiments requiring quiescent cultures, cells were grown to confluence and serum starved in media containing 0.1% serum for 48 h. The cells were stimulated on addition of media with 10% calf serum. All cells were incubated at 371 C in an atmosphere of 5% CO 2 .
Lentiviral and retroviral vectors
The lentiviral vector pLKO.1-puro expressing NS shRNA1 (targeting all variants of human NS at 5 0 -GCTAAACTGT TCTCTGTATAA-3 0 ) or NS shRNA2 (targeting all variants of human NS at 5 0 -CAGCAAGTATTGAAGTAGTAA-3 0 ) was obtained from the RNAi Consortium at the Broad Institute. Lentivirus production was achieved according to the protocol available through the RNAi Consortium, using 293T packaging cells and FuGENE 6 transfection reagent (Roche, Basel, Switzerland). HCT116-infected cells were selected in 1 mg/ml puromycin.
RNA interference (RNAi) siRNAs were transiently transfected using nucleofection (Amaxa Biosystems, Gaithersburg, MD, USA). A total of 1 Â 10 6 cells per each sample were combined with 100 ml Nucleofector solution (Amaxa Biosystems) and 1.5 mg siRNA. 
Microarray analysis
Total RNA was extracted using Trizol reagent (Invitrogen). Synthesis of double-stranded cDNA, followed by conversion to target cRNA, and hybridization to the Affymetrix Human Genome U133 array set was carried out by the manufacturer's instructions (Affymetrix). The probe arrays were washed and stained using the GeneChip Fluidics Station 400 (Affymetrix), and scanned using the Agilent GeneArray scanner (Agilent, Santa Clara, CA, USA). Data were normalized to a target intensity of 1500, and analysis was carried out using Microarray Suite 5.0, MicroDB 3.0 and Data Mining Tool 3.0 software (Affymetrix).
Quantitative real-time PCR (qPCR) Total RNA was extracted using Trizol reagent. RNA samples were treated with DNase I, and 2 mg of total RNA from each sample were reverse transcribed with a high-capacity cDNA archive kit (Applied Biosystems, Carlsbad, CA, USA). Quantitative RT-qPCR assays were performed using Fast 
Chromatin immunoprecipitation
The ChIP protocol was carried out using the ChIP Assay kit according to the manufacturers' instructions (EMD Millipore, Billerica, MA, USA). qPCR reactions were carried out using the following : rat ChIP primers: NS E-box at position -67: 0 -CGTTGCACCAAGTCAT GTGG-3 0 and 5 0 -CCTCCTCGACAGCCCTTAAA-3 0 ; as reported in (Fernandez et al., 2003; Brodsky et al., 2005) .
Immunoblot analysis
Protein lysates from exponentially growing rat fibroblasts were prepared using Laemmli buffer. Proteins were separated by 10% sodium dodecyl sulfate-PAGE and transferred to Immobilon-P membrane (EMD Millipore). Antibodies used: anti-NS (R&D Systems, Minneapolis, MN, USA); anti-GAPDH (Ambion); Secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA, USA).
Lysis of mouse organs and immunoblotting were performed as described before (De Clercq et al., 2010) . The primary antibodies used were: anti-vinculin (clone hVIN-1, Sigma, St Louis, MO, USA); anti-CD45R (B220; clone RA3-6B2, Santa Cruz, Santa Cruz, CA, USA); anti-NS (EMD Millipore); anti-myc (clone 9E10, Abcam, Cambridge, UK), antip53 (clone 1C12, 1:1000, Cell Signaling, Beverly, MA, USA); anti-caspase-3 cleaved (Cell Signaling) and anti-gH2AX (Cell Signaling). The secondary antibodies used were horseradish peroxidase-conjugated (Amersham, Amersham, UK).
Flow cytometry
As previously reported (Schorl and Sedivy, 2003) , flow cytometric analysis was performed using a BD Biosciences FACS-Caliber instrument (BD Biosciences, Franklin Lakes, NJ, USA) and CellQuest and Modfit software. Exponentially growing cells were fixed in ethanol and stained with propidium iodide (Sigma) or sulforhodamine 101 (Molecular Probes, Eugene, OR, USA). For flow-cytometric analysis of BrdU incorporation in mouse B220 þ cells, bone marrow and spleens were isolated from 6-7 week-old mice. BrdU injection of mice, magnetic sorting-based isolation of B220 þ from organs (MACS, Miltenyi Biotec, Cologne, Germany), fixation and indirect immunofluorescent BrdU labeling, were performed as described previously (De Clercq et al., 2010) .
Luminescence cell apoptosis assay B220 þ cells were isolated from bone marrow and spleens of 6-7 week-old mice using magnetic sorting (MACS, Miltenyi Biotec), as described previously (De Clercq et al., 2010) . Directly after the isolation, the cells were counted and apoptosis was measured using Caspase-3/7 Glo luminescence assays (Promega, Fitchburg, WI, USA) according to the manufacturers protocol.
Soft agar assay
The soft agar assay was performed as described . Colony growth was assessed after 2 weeks.
Mouse strains NS þ /À, Em-Myc and p53À/À mouse strains and their PCR genotyping were described earlier (Adams et al., 1986; Jacks et al., 1994; Beekman et al., 2006) . All mice were backcrossed to C57Bl/6 strain for a minimum of 10 generations. Animals displaying signs of reduced vitality or with visible tumours were euthanized.
